Search Results 7791-7800 of 33689 for oral

1. Thyroid cancer - Doctors and departments - Mayo Clinic

   ... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...

2. Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients - Mayo Clinic

   Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology) or ...

3. Safety and Tolerability of Pirfenidone in Acute Pancreatitis - Mayo Clinic

   Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks. 25 ...

4. A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer - Mayo Clinic

   Active infection requiring oral or IV antimicrobials for management within 7 days of first dose tarlatamab. Exclusion of hepatitis infection based on the ...

5. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial - Mayo Clinic

   Patients must not have known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ...

6. A Study to Evaluate the Effectiveness, Safety, and Tolerability of NLY01 in Early-stage Parkinson's Disease - Mayo Clinic

   Oral contraceptive (combined or progesterone only) in females;; Double-barrier method (any combination of physical and chemical methods);; Intrauterine device ...

7. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus ...

8. A Study to Evaluate Pembrolizumab, Ixazomib Citrate, and Dexamethasone to Treat Participants with Relapsed Multiple Myeloma - Mayo Clinic

   Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing.

9. Vasculitis Clinical Trials - Mayo Clinic Research

   ... oral corticosteroids (OCS) ≤ 4mg/day) at both Week 36 and Week 52. The aim of this study is to investigate the effectiveness and safety of depemokimab 200 ...

10. Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery - Mayo Clinic

    NOTE: PET-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast. Patients ...